Ruling Affirms Patent Claim for Paragon BioTeck’s R-Phenylephrine Hydrochloride Formulation

PORTLAND, Ore., — Paragon BioTeck, Inc., announces a monumental ruling handed down by the United States Patent and Trademark Office (USPTO) affirming claims made by Paragon in the patent for its R-phenylephrine hydrochloride formulation. Paragon is a privately held pharmaceutical and medical device company specializing in the development and commercialization of ophthalmic pharmaceuticals, devices and therapies.

eAgile Announces partnership with Heinlein Plastik to bring eSeal RFID Solution to Europe

GRAND RAPIDS, Mich. — eAgile Inc.,, a global leader in radio frequency identification (RFID) technologies, announces a partnership with Heinlein Plastik-Technik GmbH to bring RFID smart packaging solutions to the European cap and closure marketplace. eSeal is the first turnkey solution engineered to integrate the benefits of RFID into the billions of caps and closures consumed by the over-the-counter pharmaceutical, nutraceutical, cosmetic and chemical manufacturers.

Join Brandy Vaughan of LearnTheRisk.org for Important and Free Talk ‘Is Your Health For $ale?’ in San Francisco

SAN FRANCISCO, Calif. — Join Brandy Vaughan, former Merck pharmaceutical rep and founder of LearnTheRisk.org, a campaign of the Council for Vaccine Safety, for a FREE talk on Sunday, Sept. 25, 2016 at 1 p.m. in San Francisco, as she exposes the dark side of today’s ‘health’care system and explains how we can stay healthy in a system that wants to keep us sick.

Paragon BioTeck, Inc. Announces Call for 2017 Koch Kellan Scholarship Applicants

PORTLAND, Ore. — Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, announced today a call for applications for the 2017 Koch Kellan Scholarship, awarded annually to an outstanding graduate medical student committed to pursuing a clinical, teaching or research career in ophthalmology. A Paragon Gives initiative, the Koch Kellan Scholarship reinforces the fundamental mission of Paragon BioTeck to drive innovations to address unmet and underserved medical needs and improve the quality of lives around the world.

Pharma companies gain competitive advantage from 1 day Masterclass on Artificial Intelligence in Pharma sales and marketing

NEW YORK, N.Y. — Eularis announces the release of their one-day Masterclass “Using Artificial Intelligence to Transform Sales and Revenue: What Pharma Need to Know.” Many Pharma sales and marketing teams do not understand the relevance, nor the critical importance, of AI to achieve stronger results in their roles, and believe it is not relevant to them or their job. This is an incorrect assumption.

Sarasota Attorney M David Shapiro Comments on Landmark $70 Million ADHD Drug Risperdal Lawsuit

SARASOTA, Fla. — The Sarasota Florida attorney commented after a Philadelphia jury returned a verdict of $70 million against Johnson and Johnson for failing to warn of the risks associated for taking Risperdal. The case involved a sixteen-year-old boy who developed breast from the medication prescribed for attention deficit disorder (ADHD).

Paragon BioTeck Signs Exclusive Distribution Agreement with Horus Pharma for Ilast

freeNewsArticles Story Summary: Paragon BioTeck, Inc. signs a distribution agreement with Horus Pharma for rights to supply the Ilast range of its medical-grade ocular hygiene and lid care products within the United States. It begins on an exclusive basis this month.

Heart Imaging Technologies Wins $2.5M NIH Grant for Clinical Trials

freeNewsArticles Story Summary: Heart Imaging Technologies (HeartIT), the global leader that pioneered the first FDA approved zero-footprint medical imaging workstation, announced today that it has received a $2.5M grant from the National Institutes of Health in order to develop the ‘Cloud Based Corelab of the Future.’

Bausch + Lomb Signs Exclusive License Agreement with Paragon BioTeck for Phenylephrine

freeNewsArticles Story Summary: Bausch + Lomb, the global eye health company and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon’s phenylephrine in the United States on an exclusive basis beginning this month.

CMI’s Paul Gondek and Alisa Hamilton to Co-Present with Deanna Schwarz of Pfizer at 2013 PRMG Annual National Conference

freeNewsArticles Story Summary: CMI and Pfizer Inc. (NYSE:PFE) will co-present ‘Engaging Stakeholders with A Story – 3 Tips to Improve Research Reporting’ at the PMRG’s upcoming National Annual Conference March 10-12, 2013 in National Harbor, Maryland.